Compare ZLAB & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZLAB | SUPN |
|---|---|---|
| Founded | 2013 | 2005 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.5B |
| IPO Year | 2017 | 2010 |
| Metric | ZLAB | SUPN |
|---|---|---|
| Price | $22.62 | $40.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 12 | 4 |
| Target Price | $33.14 | ★ $61.75 |
| AVG Volume (30 Days) | ★ 712.3K | 624.7K |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.46 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $460,156,000.00 | $392,755,000.00 |
| Revenue This Year | N/A | $23.21 |
| Revenue Next Year | $26.50 | $54.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 15.33 | N/A |
| 52 Week Low | $15.96 | $40.51 |
| 52 Week High | $30.00 | $59.68 |
| Indicator | ZLAB | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 34.34 | 36.12 |
| Support Level | $16.97 | $40.51 |
| Resistance Level | $27.14 | $52.33 |
| Average True Range (ATR) | 1.03 | 1.51 |
| MACD | -0.36 | -0.08 |
| Stochastic Oscillator | 9.48 | 4.73 |
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.